Eliquis® (apixaban) – New indication, new formulation
April 17, 2025 - The FDA approved Bristol Myers Squibb’s Eliquis (apixaban), for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment.
Top